癌症治疗市场按分销管道、药物类型、癌症类型、治疗方法、给药途径和地区划分

2025 年全球抗癌药物市场规模估计为 2,612.2 亿美元，预计到 2032 年将达到 6,073.6 亿美元，2025 年至 2032 年的复合年增长率为 12.8%。

图。

抗癌药是指用于治疗癌性肿瘤的药物。由于各种癌症发病率的上升，全球抗癌药物市场在过去几年一直稳定成长。根据世界卫生组织 (WHO) 的数据，自 2000 年以来，全球癌症发生率几乎翻了一番，预计到 2040 年全球整体发生率将增加 50%。肺癌、结肠癌、乳癌和摄护腺癌等癌症发生率上升是推动抗癌药物需求的主要因素。此外，老年人口的增加以及吸烟、饮酒、饮食不良、缺乏运动等生活习惯的改变也在增加罹患癌症的风险，从而增加癌症治疗药物的销售量。大量新型药物分子和治疗方法以及标靶治疗的出现进一步推动了市场扩张。然而，高昂的治疗费用仍是阻碍抗癌药物广泛使用的瓶颈。

市场动态

全球抗癌药物市场受到世界各地各种癌症发生率不断上升的推动。根据提供全球癌症统计数据的基于网路的互动式平台 GLOBOCAN 的数据，2020 年全球将有约 1,930 万例新发癌症病例和 1,000 万人死亡。肺癌仍然是癌症死亡的主要原因。标靶治疗的需求不断增长以及学名药的易得性为市场提供了巨大的成长机会。然而，严格的监管措施、市场开发的高研发成本以及临床测试的高失败率是限制市场成长的一些因素。此外，重磅药物专利到期也对各大公司的收益负面影响。随着人们认识的提高、医疗支出的增加以及对优质抗癌药物的需求，亚太地区的新兴市场正以巨大的潜力开闢新的道路。

研究的主要特点

• 本报告对全球肿瘤药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球抗癌药物市场的主要企业已根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行了分析。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 本报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员可以透过全球抗癌药物市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场预测

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 管道分析
• 专利到期清单（2018-2031）
• 投资研发
• 赎回情况
• 合併与收购
• 合作
• 流行病学
• PEST分析

第四章 全球抗癌药物市场-冠状病毒（COVID-19）大流行的影响

• 整体影响
• COVID-19 市场影响

5. 2020 年至 2032 年全球抗癌药物市场（按药物类型划分）（十亿美元）

• 介绍
• 细胞毒性药物
• 烷化剂
• 抗代谢物
• 其他的
• 标靶药物
• 单株抗体
• 蛋白酪氨酸激酶抑制剂
• 其他的
• 荷尔蒙
• 卵巢功能抑制剂
• 雌激素生成抑制剂
• 其他的
• 其他的

6. 2020-2032 年全球抗癌药物市场（按癌症类型划分）（十亿美元）

• 介绍
• 肺癌
• 乳癌
• 大肠直肠癌
• 摄护腺癌
• 血癌
• 膀胱癌
• 其他的

7. 全球抗癌药物市场，依治疗方法，2020-2032 年（十亿美元）

• 介绍
• 化疗
• 标靶治疗
• 免疫疗法
• 其他的

8. 2020 年至 2032 年按给药途径分類的全球肿瘤药物市场（十亿美元）

• 介绍
• 口服
• 母亲和孩子
• 肌肉注射

9. 2020-2032 年全球抗癌药物市场按分销管道划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

第 10 章。

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
  • 波湾合作理事会
  • 以色列
  • 其他中东地区
• 非洲
  • 北非
  • 中部非洲
  • 南非

第十一章 竞争格局

• 热图分析
• 公司简介
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Gilead Sciences Inc.
  • Bristol-Myers Squibb
  • Amgen Inc.
  • Sanofi AG
  • F. Hoffmann-La Roche AG
  • Merck &Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company
  • Daiichi Sankyo

第 12 章 分析师观点

• 兴衰
• 一致的机会地图

第十三章参考文献与调查方法

• 参考
• 调查方法

Global Oncology Drugs Market is estimated to be valued at USD 261.22 Bn in 2025 and is expected to reach USD 607.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.8% from 2025 to 2032.

Figure. Oncology Drugs Market Share (%), By Region 2025

Oncology drugs refer to medications that are used for treating cancerous tumors. The global oncology drugs market has been witnessing steady growth over the past few years owing to the rising prevalence of various types of cancers. According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by 50% globally by 2040. The increasing incidences of lung cancer, colorectal cancer, breast cancer, and prostate cancer are the major factors fueling the demand for oncology drugs. Furthermore, the growing geriatric population and changing lifestyle habits such as tobacco smoking, alcohol consumption, poor diet, and lack of physical activity have also raised the risk of developing cancer which has augmented the sales of oncology medications. A robust pipeline of novel drug molecules and therapies along with the emergence of targeted therapies are further catalyzing market expansion. However, high treatment cost remains a bottleneck, restraining the broader adoption of cancer medications.

Market Dynamics:

The global oncology drugs market is driven by the rising prevalence of various cancer types worldwide. As per GLOBOCAN, an interactive web-based platform presenting global cancer statistics, there were around 19.3 million new cancer cases and 10 million cancer deaths globally in 2020. Lung cancer remains the leading cause of cancer death. The increasing demand for targeted therapies and easy availability of generic medications are providing huge growth opportunities in the market. However, factors such as stringent regulatory policies, high R&D costs involved in drug development, and frequent drug failures in clinical trials are impeding the market growth. Furthermore, patent expiry of blockbuster drugs is negatively impacting the revenues of major players. Nonetheless, emerging markets in Asia Pacific are opening up new avenues by offering potential future opportunities driven by growing awareness, healthcare spending, and demand for quality cancer treatment.

Key Features of the Study:

• This report provides an in-depth analysis of the global oncology drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, BeiGene LTD, Astellas Pharma Inc., AbbVie Inc., Takeda Pharmaceutical Company, and Daiichi Sankyo
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology drugs market

Market Segmentation

• Drug Type
  • Cytotoxic Drugs
  • Alkylating Agents
  • Antimetabolites
  • Others
  • Targeted Drugs
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
  • Others
  • Hormonal Drugs
  • Ovarian Function Blockers
  • Estrogen Production Blockers
  • Others
• Cancer Type:
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer
  • Bladder Cancer
  • Other
• Therapy:
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
• Route of Administration:
  • Oral
  • Parental
  • Intramuscular
  • Intravenous
  • Subcutaneous
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Sanofi AG
  • F.Hoffmann-La Roche AG
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company
  • Daiichi Sankyo

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Therapy
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Pipeline Analysis
• Patent Expiry List (2018-2031)
• Investments for R&D
• Reimbursement Scenario
• Mergers & Acquisitions
• Collaborations
• Epidemiology
• PEST Analysis

4. Global Oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic:

• Overall Impact
• COVID-19 Impact on the Market

5. Global Oncology Drugs Market, By Drug Type, 2020 - 2032, (USD BN)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Cytotoxic Drug
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Alkylating Agents
• Antimetabolites
• Others
• Targeted Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors
• Others
• Hormonal Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Ovarian Function Blockers
• Estrogen Production Blockers
• Others
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Oncology Drugs Market, By Cancer Type,2020 - 2032, (USD BN)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Oncology Drugs Market, By Therapy, 2020 - 2032, (USD BN)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Oncology Drugs Market, By Route of Administration, 2020 - 2032, (USD BN)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Parental
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Intramuscular
  • Intravenous
  • Subcutaneous

9. Global Oncology Drugs Market, By Distribution Channel, 2020 - 2032, (USD BN)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

10. Global Oncology Drugs Market, By Region, 2020 - 2032, (USD BN)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

11. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Pfizer Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Novartis AG
  • AstraZeneca PLC
  • Gilead Sciences Inc.
  • Bristol-Myers Squibb
  • Amgen Inc.
  • Sanofi AG
  • F. Hoffmann-La Roche AG
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company
  • Daiichi Sankyo

12. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact